Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05479045 · ClinicalTrials.gov registry record · Phase 2
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
A Phase 2 study, sponsored by Georgetown University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT05479045 is a Phase 2 study that has not yet begun recruiting, run by Georgetown University. The registered enrollment target is 24 participants.
The verdict
NCT05479045, a Phase 2 study, has not yet begun recruiting, sponsored by Georgetown University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is an open label, non-randomized, 2-stage phase II, single arm study to determine the efficacy of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide vaccine as a priming mechanism to prevent anti-PD1 resistance in patients with platinum-refractory stage III/IV ovarian cancer (OC).
Interventions
- DRUG Toripalimab-tpzi
- BIOLOGICAL NY-ESO-1 Peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-09 |
| Est. Completion | 2028-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05479045
The ClinicalTrials.gov registry entry for NCT05479045 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Toripalimab-tpzi is the first listed.
NCT05479045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05479045 about?
NCT05479045 is a clinical study titled "A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients". This is an open label, non-randomized, 2-stage phase II, single arm study to determine the efficacy of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide vaccine as a priming mechanism to prevent anti-PD1 resistance in patients with platinum-refractory stage III/IV ovarian cancer (OC).
What is the current status of trial NCT05479045?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2026-09. Estimated completion is 2028-11.
What interventions are being tested in trial NCT05479045?
The interventions under investigation include: Toripalimab-tpzi (DRUG), NY-ESO-1 Peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05479045?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.